Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Gurska LM, Okabe R, Schurer A, Tong MM, et al. Clin Cancer Res 2023;29:943-956.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gurska LM, Okabe R, Schurer A, Tong MM, et al. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clin Cancer Res 2023;29:943-956.
PMID: 36537918